Trial reportEuropean journal of nutrition2017
FUT2-dependent breast milk oligosaccharides and allergy at 2 and 5 years of age in infants with high hereditary allergy risk.
Trial report in European journal of nutrition, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00298337 (Use of Probiotic Bacteria in Prevention of Allergic Disease in Children 1999-2008), which is not on this map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Use of Probiotic Bacteria in Prevention of Allergic Disease in Children 1999-2008
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 122 citations in OpenAlex.
- Probiotics in infants for prevention of allergic disease.The Cochrane database of systematic reviews · 2025Pooled it
- Trial
- Effects of Infant Formula With Human Milk Oligosaccharides on Growth and Morbidity: A Randomized Multicenter Trial.Journal of pediatric gastroenterology and nutrition · 2017Trial
- An exploratory analysis of the associations of human milk oligosaccharides and N-/O-glycans with infectious and allergic outcomes in the first year of life: the Japanese Human Milk Study Cohort.European journal of nutrition · 2026Article
- Article
- Characterization of human milk oligosaccharides from Chinese mothers and their association with delivery mode and infant eczema.Frontiers in nutrition · 2026Article
- Secretor status-dependent modulation ofFrontiers in nutrition · 2026Article
- "Microbial and immune modulation by 2'-fucosyllactose supplementation during gestation: a strategy to prevent food allergies".Gut microbes · 2025Article
- Article
- Human gut prophage landscape identifies a prophage-mediated fucosylation mechanism alleviating colitis.Nature communications · 2025Article
- Influence of infant fucosyltransferase polymorphisms on the association of maternal secretor status with child outcomes: the Ulm birth cohort studies.Scientific reports · 2025Article
- The potential immunomodulatory role of human milk oligosaccharides in prevention of viral infections and development of asthma in early life.Frontiers in immunology · 2025Review
- Secretor and non-secretor human milk oligosaccharides differentially modulate immune response in the presence of cow's milk allergen β-lactoglobulin in anFrontiers in immunology · 2025Article
- Human milk oligosaccharides are associated with maternal genetics and respiratory health of human milk-fed children.Nature communications · 2024Article
- Maternal influences on offspring food allergy.Immunological reviews · 2024Review
- 2'-Fucosyllactose helps butyrate producers outgrow competitors in infant gut microbiota simulations.iScience · 2024Article
- Interactions of human milk oligosaccharides with the immune system.Frontiers in immunology · 2024Review
- Infant Fecal Fermentations with Galacto-Oligosaccharides and 2'-Fucosyllactose Show DifferentialChildren (Basel, Switzerland) · 2023Article
- Role of human milk oligosaccharide metabolizing bacteria in the development of atopic dermatitis/eczema.Frontiers in pediatrics · 2023Review
- Breastfeeding and Allergy Effect Modified by Genetic, Environmental, Dietary, and Immunological Factors.Nutrients · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeManifestation of allergic disease depends on genetic predisposition, diet and commensal microbiota. Genetic polymorphism of mothers determines their breast milk glycan composition. One major determinant is the fucosyltransferase 2 (FUT2, secretor gene) that was shown to be linked to commensal microbiota establishment. We studied whether FUT2-dependent breast milk oligosaccharides are associated with allergic disease in breast-fed infants later in life.
methodsWe analyzed FUT2-dependent oligosaccharides in breast milk samples of mothers (n = 266) from the placebo group of a randomized placebo-controlled trial of prebiotics and probiotics as preventive against allergic disease in infants with high allergy risk (trial registry number: NCT00298337). Using logistic regression models, we studied associations between FUT2-dependent breast milk oligosaccharides and incidence of allergic disease at 2 and 5 years of age.
resultsAt 2 years, but not at 5 years of age, we observed a presumed lower incidence (p < 0.1) for IgE-associated eczema manifestation in C-section-born infants who were fed breast milk containing FUT2-dependent oligosaccharides. By logistic regression, we observed a similar relation (p < 0.1) between presence of FUT2-dependent breast milk oligosaccharides and IgE-associated disease and IgE-associated eczema in C-section-born infants only. When testing with the levels of breast milk oligosaccharide 2'-fucosyllactose as proxy for FUT2 activity, we observed significant (p < 0.05) associations in the C-section-born infants with 'any allergic disease,' IgE-associated disease, eczema and IgE-associated eczema.
conclusionThe data indicate that infants born by C-section and having a high hereditary risk for allergies might have a lower risk to manifest IgE-associated eczema at 2 years, but not 5 years of age, when fed breast milk with FUT2-dependent milk oligosaccharides. Further studies with larger cohorts and especially randomized controlled intervention trials are required to build on these preliminary observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.